AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35501309
Drug: (2R,6R)-HNK (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2R,6R)-HNK (10 mg/kg)
Trial: 35501592
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg single oral dose
Trial: 35503163
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg qw
Trial: 35503163
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg q2w
Trial: 35503163
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg qw or q2w
Trial: 35503244
Drug: Sunnyside (6-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunnyside (6-week cognitive behavioral therapy-based web-based intervention)
Trial: 35503244
Drug: Sunnyside Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunnyside Plus (6-week cognitive behavioral therapy-based web-based intervention with additional education and support for human milk feeding)
Trial: 35505238
Drug: Intradermal reaction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal reaction (IDR) test in likely insulin allergy patients
Trial: 35505238
Drug: Intradermal reaction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal reaction (IDR) test in possible insulin allergy patients
Trial: 35505238
Drug: Intradermal reaction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal reaction (IDR) test in unlikely insulin allergy patients
Trial: 35505238
Drug: Intradermal reaction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal reaction (IDR) test in case-control study
Trial: 35505238
Drug: Skin prick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin prick and serum anti-insulin IgE tests in case-control study
Trial: 35506108
Drug: GSK2586881 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586881 (0.1, 0.2, 0.4, or 0.8 mg/kg, single intravenous dose)
Trial: 35506190
Drug: Daily mango
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mango consumption, dosage not specified, duration not specified
Trial: 35507014
Drug: Doxorubicin-cyclophosphamide-based neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-cyclophosphamide-based neoadjuvant therapy
Trial: 35507355
Drug: Standard 2-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 2-dose SARS-CoV-2 vaccination regimen
Trial: 35507355
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of SARS-CoV-2 vaccine
Trial: 35507396
Drug: CDSS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDSS intervention in treatment practices
Trial: 35507396
Drug: CDSS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDSS intervention in treatment practices (subgroup analysis)
Trial: 35507739
Drug: Maralixibat 266
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat 266 μg/kg orally, once daily, from baseline to Week 72, with twice-daily dosing permitted from Week 72.
Trial: 35507774
Drug: Placebo cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cooling patch intervention
Trial: 35507774
Drug: Placebo cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cooling patch intervention for DFU
Trial: 35508346
Drug: Ustekinumab induction
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab induction dose
Trial: 35509022
Drug: Magnetically controlled
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetically controlled capsule endoscopy (MCE)
Trial: 35509022
Drug: Magnetically controlled
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetically controlled capsule endoscopy (MCE) with magnetic steering
Trial: 35510711
Drug: Anticoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation treatment (e.g., low-molecular-weight heparin)
Trial: 35510711
Drug: No anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulation treatment
Trial: 35511148
Drug: MRG003 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRG003 (0.1 to 2.5 mg/kg administered every 3 weeks during phase 1a; recommended dose of 2.5 mg/kg during phase 1b)
Trial: 35511170
Drug: Appropriate medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate medical therapy
Trial: 35511740
Drug: IMGC936 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMGC936 (a next-generation maytansinoid-based antibody-drug conjugate)
Trial: 35511920
Drug: Orally delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine
Trial: 35511920
Drug: Intranasally delivered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine
Trial: 35512229
Drug: Non-recommended edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-recommended edoxaban dose regimens
Trial: 35512742
Drug: Intraoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiotherapy (IORT) with adjuvant gemcitabine-based chemotherapy administered 8-12 weeks after surgery.
Trial: 35512743
Drug: Clopidogrel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel treatment with VerifyNow assay results
Trial: 35513751
Drug: One occurrence
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One occurrence of hyperchloremia (serum chloride levels ≥110 mmol/L) within 72 hours
Trial: 35513751
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or more occurrences of hyperchloremia (serum chloride levels ≥110 mmol/L) within 72 hours
Trial: 35513826
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of LMWH (> 100 IU/kg/day)
Trial: 35513826
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose of LMWH (≤ 100 IU/kg/day)
Trial: 35513826
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose of LMWH
Trial: 35514201
Drug: Eculizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (1200 mg IV on Day 1, additional doses of 1200 mg IV on Days 4 and 8; 900 mg IV on Days 15 and 22; optional doses on Days 12 and 18)
Trial: 35514770
Drug: Treprostinil inhalation
RxNorm normalized name: treprostinil Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treprostinil inhalation powder (TreT)
Trial: 35514770
Drug: Treprostinil inhalation
RxNorm normalized name: treprostinil Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treprostinil inhalation solution
Trial: 35518121
Drug: Vibrating capsule
RxNorm normalized name: VIBRATING DEVICE,CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrating capsule (VC), two capsules per week for six weeks
Trial: 35521657
Drug: Durvalumab (MEDI4736)
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (MEDI4736) with Tremelimumab in combination with image-guided stereotactic body radiotherapy
Trial: 35522941
Drug: PD-L1/TIGIT bispecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-L1/TIGIT bispecific antibody
Trial: 35523118
Drug: Desmopressin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin administered IV
Trial: 35524015
Drug: Patient-specific PEEK
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific PEEK implant
Trial: 35524239
Drug: Alpelisib 350
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib 350 mg QD combined with Imatinib 400 mg QD
Trial: 35525964
Drug: STOP (Self-regulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STOP (Self-regulation Therapy for Opioid addiction and Pain)
Trial: 35526096
Drug: ABL501 (LAG-3xPD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABL501 (LAG-3xPD-L1 bispecific antibody)
Trial: 35526096
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PD-1/PD-L1 blockade with other checkpoint inhibitors
Trial: 35526308
Drug: Regorafenib 80
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 80 mg and Nivolumab 240 mg every 2 weeks
Trial: 35526554
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative treatment (982 patients)
Trial: 35527353
Drug: Poor self-reported
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor self-reported oral health
Trial: 35527798
Drug: Online Mindfulness-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Mindfulness-Based Cognitive Therapy (MBCT)
Trial: 35529085
Drug: Finerenone (nonsteroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Trial: 35530041
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment algorithm including non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, oxygen therapy, and antibiotics.
Trial: 35533265
Drug: Pre-meal and
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-meal and basal insulin omission
Trial: 35533793
Drug: Amoxicillin (TDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (TDM with ≥1 intermediate and ≥1 trough level performed 24 h after therapy initiation)
Trial: 35534083
Drug: Daily stress
RxNorm normalized name: Natrol Daily Stress Relief Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily stress
Trial: 35534310
Drug: Rotavirus vaccine
RxNorm normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotavirus vaccine (Rotarix®)
Trial: 35534690
Drug: Induction chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemo-immunotherapy (ICIT)
Trial: 37314665
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept 125 mg once weekly
Trial: 35536617
Drug: Biological age
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological age estimation model using 9 physiological biomarkers
Trial: 35536669
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CSA) at a starting dose of 9 mg/kg/d
Trial: 35537101
Drug: Obinutuzumab 1000
RxNorm normalized name: obinutuzumab 1000 MG in 40 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab 1000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 to 6, followed by obinutuzumab maintenance every 2 months for 2 years; Venetoclax 800 mg OD continuously for 6 cycles starting on day 2 of cycle 1
Trial: 35537111
Drug: AKST4290 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKST4290 (400 mg) orally twice daily for 6 weeks
Trial: 35537411
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor blockade
Trial: 35537782
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg intravenously every 3 weeks) plus famitinib (20 mg orally once daily)
Trial: 35538105
Drug: De-escalated adjuvant
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalated adjuvant antibody doublet therapy (trastuzumab and pertuzumab) without chemotherapy
Trial: 35538502
Drug: Pharmacological and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological and non-pharmacological treatments
Trial: 35538502
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (SLT)
Trial: 35538512
Drug: NI-1701 (CD47xCD19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NI-1701 (CD47xCD19 bispecific antibody)
Trial: 35544727
Drug: First- or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First- or second-line systemic therapy for advanced/metastatic CCA
Trial: 35544759
Drug: 1% chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chloroprocaine (40 mL)
Trial: 35544759
Drug: 2% chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chloroprocaine (40 mL)
Trial: 35544759
Drug: 3% chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% chloroprocaine (40 mL)
Trial: 35545011
Drug: Anti-S100A8/A9 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-S100A8/A9 antibody
Trial: 35545011
Drug: Flo1-2a anti-murine
RxNorm normalized name: Murine Ear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flo1-2a anti-murine anti-IL-1α monoclonal antibody
Trial: 35545011
Drug: XB2001 (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XB2001 (specific anti-human IL-1α antibody)
Trial: 35545657
Drug: Self-managed lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-managed lifestyle treatment using a digital tool
Trial: 35545778
Drug: Pevonedistat alone
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat alone or in combination with azacitidine
Trial: 35546043
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg) for 8 weeks
Trial: 35546396
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and stabilization occlusal splint
Trial: 35546401
Drug: Pronolis®HD mono
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pronolis®HD mono 2.5% (high-density sterile viscoelastic solution of hyaluronic acid)
Trial: 35546402
Drug: 4-hydroxysalicylanilide (HDS)
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hydroxysalicylanilide (HDS) in combination with melphalan and bortezomib
Trial: 35546414
Drug: Ramosetron ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron ODT 0.1 mg administered after discharge on postoperative days 1 and 2
Trial: 35546414
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (metoclopramide 10 mg administered only when nausea/vomiting occurred)
Trial: 35546555
Drug: Anakinra (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100-300 mg administered intravenously for 15 days)
Trial: 35546669
Drug: Eribulin (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin (1.4 mg/m² initial dose)
Trial: 35548446
Drug: Reduced bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced bolus bivalirudin (80% of normal dose)
Trial: 35549674
Drug: Spartalizumab in
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Spartalizumab in combination with FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Trial: 35550037
Drug: COVID-19 vaccines
RxNorm normalized name: Covid-19 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccines (various Emergency Use Authorization or licensed formulations)
Trial: 37993355
Drug: Ebola vaccine
RxNorm normalized name: ebola vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebola vaccine trial
Trial: 35551072
Drug: Surpass flow
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surpass flow diverter treatment
Trial: 35551087
Drug: Therapeutic plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic plasma exchange (TPE) on days 5-7, in addition to standard of care radiotherapy and immunotherapy.
Trial: 35551087
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care radiotherapy and immunotherapy.
Trial: 35551366
Drug: SARS-CoV-2 mRNA
RxNorm normalized name: SARS-CoV-2 mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 mRNA vaccines (mRNA-1273, BNT162b2)
Trial: 35552391
Drug: FET-PET-based SIB
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FET-PET-based SIB intensity-modulated radiotherapy (78 Gy total dose, 2.6 Gy per fraction)
Trial: 35552827
Drug: Tinzaparin (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin (fixed dose, 10,000 Anti-Xa IU, OD)
Trial: 35558645
Drug: Opioid prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid prescriptions at discharge
Trial: 35558645
Drug: Alcohol and
RxNorm normalized name: Polyvinyl alcohol and povidone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol and other drugs (AOD) status
Trial: 35559387
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis combined with mechanical thrombectomy (Group A)
Trial: 35559387
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment and intravenous thrombolysis (Group B)
Trial: 35566502
Drug: Age, time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, time since COVID-19, hospitalization, dizziness, joint pain, pre-existing cardiopulmonary disease, use of beta blockers
Trial: 37393513
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of nusinersen
Trial: 35567345
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg dose of nusinersen
Trial: 35567422
Drug: Risdiplam, orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risdiplam, orally once daily for a median duration of 4.8 months (range, 0.3-9.2 months)
Trial: 35567560
Drug: sLOX-1 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sLOX-1 levels in ACS patients undergoing serial intracoronary imaging and statin therapy
Trial: 35567881
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) analysis applied to 3D maxillofacial shapes
Trial: 35567881
Drug: 3D geometric
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D geometric morphometrics combined with ML
Trial: 35567914
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus an aromatase inhibitor (P+AI)
Trial: 35568047
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of bone marrow-derived allogeneic mesenchymal stromal cells (MSCs)
Trial: 35568909
Drug: Precision cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision cancer drugs through IMPRESS-Norway
Trial: 35570280
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (SGLT2-I)
Trial: 35570280
Drug: Other oral
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oral anti-diabetic agents (non-SGLT2-I)
Trial: 35570383
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg) combined with aspirin
Trial: 35570983
Drug: VIS649 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS649 0.5 mg/kg
Trial: 35570983
Drug: VIS649 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS649 2.0 mg/kg
Trial: 35570983
Drug: VIS649 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS649 6.0 mg/kg
Trial: 35570983
Drug: VIS649 12.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS649 12.0 mg/kg
Trial: 35570983
Drug: VIS649 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIS649 6.0 mg/kg + vaccine
Trial: 35571928
Drug: IQP-AE-103 (proprietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IQP-AE-103 (proprietary combination of dehydrated okra powder and inulin)
Trial: 35572740
Drug: PVP-I nasal
RxNorm normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PVP-I nasal spray (NS) at diluted concentrations of 0.5%